The ASCEND-HF trial: An acute study of clinical effectiveness of nesiritide and decompensated heart failure

Sanjay Dandamudi; Horng H. Chen

doi:10.1586/erc.12.31

The ASCEND-HF trial: An acute study of clinical effectiveness of nesiritide and decompensated heart failure

Sanjay Dandamudi, Horng H. Chen

Research output: Contribution to journal › Review article

12 Scopus citations

Abstract

Nesiritide has been approved by the US FDA for the treatment of acute decompensated heart failure since 2001. Subsequently, two meta-analyses questioned its impact on mortality and association with worsening renal function. Therefore, the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial was designed to assess the safety and efficacy of nesiritide in acute decompensated heart failure based on clinically relevant outcomes. In this article, the important findings and lessons learned from this landmark study are reviewed and potential evolving roles for nesiritide and natriuretic peptides in the future of heart failure therapy are proposed.

Original language	English (US)
Pages (from-to)	557-563
Number of pages	7
Journal	Expert Review of Cardiovascular Therapy
Volume	10
Issue number	5
DOIs	https://doi.org/10.1586/erc.12.31
State	Published - May 1 2012

Keywords

ASCEND-HF
heart failure
heart failure therapy
natriuretic peptides
nesiritide

ASJC Scopus subject areas

Internal Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1586/erc.12.31

Fingerprint Dive into the research topics of 'The ASCEND-HF trial: An acute study of clinical effectiveness of nesiritide and decompensated heart failure'. Together they form a unique fingerprint.

Cite this

Dandamudi, S., & Chen, H. H. (2012). The ASCEND-HF trial: An acute study of clinical effectiveness of nesiritide and decompensated heart failure. Expert Review of Cardiovascular Therapy, 10(5), 557-563. https://doi.org/10.1586/erc.12.31

@article{a78d01304acd4d1ba09a0b755070a322,

title = "The ASCEND-HF trial: An acute study of clinical effectiveness of nesiritide and decompensated heart failure",

abstract = "Nesiritide has been approved by the US FDA for the treatment of acute decompensated heart failure since 2001. Subsequently, two meta-analyses questioned its impact on mortality and association with worsening renal function. Therefore, the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial was designed to assess the safety and efficacy of nesiritide in acute decompensated heart failure based on clinically relevant outcomes. In this article, the important findings and lessons learned from this landmark study are reviewed and potential evolving roles for nesiritide and natriuretic peptides in the future of heart failure therapy are proposed.",

keywords = "ASCEND-HF, heart failure, heart failure therapy, natriuretic peptides, nesiritide",

author = "Sanjay Dandamudi and Chen, {Horng H.}",

year = "2012",

month = may,

day = "1",

doi = "10.1586/erc.12.31",

language = "English (US)",

volume = "10",

pages = "557--563",

journal = "Expert Review of Cardiovascular Therapy",

issn = "1477-9072",

publisher = "Expert Reviews Ltd.",

number = "5",

}

TY - JOUR

T1 - The ASCEND-HF trial

T2 - An acute study of clinical effectiveness of nesiritide and decompensated heart failure

AU - Dandamudi, Sanjay

AU - Chen, Horng H.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Nesiritide has been approved by the US FDA for the treatment of acute decompensated heart failure since 2001. Subsequently, two meta-analyses questioned its impact on mortality and association with worsening renal function. Therefore, the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial was designed to assess the safety and efficacy of nesiritide in acute decompensated heart failure based on clinically relevant outcomes. In this article, the important findings and lessons learned from this landmark study are reviewed and potential evolving roles for nesiritide and natriuretic peptides in the future of heart failure therapy are proposed.

AB - Nesiritide has been approved by the US FDA for the treatment of acute decompensated heart failure since 2001. Subsequently, two meta-analyses questioned its impact on mortality and association with worsening renal function. Therefore, the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure trial was designed to assess the safety and efficacy of nesiritide in acute decompensated heart failure based on clinically relevant outcomes. In this article, the important findings and lessons learned from this landmark study are reviewed and potential evolving roles for nesiritide and natriuretic peptides in the future of heart failure therapy are proposed.

KW - ASCEND-HF

KW - heart failure

KW - heart failure therapy

KW - natriuretic peptides

KW - nesiritide

UR - http://www.scopus.com/inward/record.url?scp=84861860333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861860333&partnerID=8YFLogxK

U2 - 10.1586/erc.12.31

DO - 10.1586/erc.12.31

M3 - Review article

C2 - 22651831

AN - SCOPUS:84861860333

VL - 10

SP - 557

EP - 563

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 5

ER -